TOP > Greeting
Message from the President of the 57th Annual Meeting of the Japan Society of Clinical Oncology

Kazuhiro Yoshida M.D., Ph.D.
(Department of Surgical Oncology, Graduate School of Medicine, Gifu University)
It is a great honor for me and my colleagues to host the coming meeting of our long-established society. Annual meetings in the past have been presided over by my former teacher Professor Shigetoyo Saji at Gifu University (37th meeting in 1999), Professor Takao Hattori at Hiroshima University (23rd meeting in 1985), Professor Tetsuya Toge (39th meeting in 2001), and Professor Masahiko Nishiyama at Gunma University (49th meeting in 2011), all of which greatly impressed me.
The main theme of the meeting is “TACKLING THE NEEDS OF SOCIETY AND MEDICINE” We must properly respond to the dramatically changing social and medical needs in this aging society. We have recently witnessed remarkable technical advances, particularly in the field of artificial intelligence (AI). In relation to clinical practice, much work is being done on precision medicine, including genomic medicine and a wide variety of molecular targeted drugs. Furthermore, as reflected in the work that won the Nobel Prize in Physiology or Medicine in 2018, cancer immunotherapies, including immune checkpoint inhibitors, are playing an important role in cancer treatment. These new medical practices will continue to advance when combined with AI. On the other hand, there is a wide variety of adverse events affecting the heart, skin, and other parts of the body caused by Immune-Related Adverse Events (irAE), chemotherapies and molecular targeted drugs. Accordingly, team-based practice across multiple departments is required. Against this background and the trend toward globalization, our annual meetings provide an important opportunity for reviewing cancer treatment in Japan and future plans.
The coming meeting will feature attractive programs focusing on the following topics: (1) AI-based future planning for advanced medicine and industry-academia collaboration,
(2) Verification of precision medicine: new medical modalities, including genomic medicine, molecular targeted drugs, and immunotherapies, and newer medical services arising from their combination, (3) Cancer treatment in the global era: collaboration of the three academic societies of JSCO, JSMO, and JCA, an international joint symposium with ASCO, ESMO, ECCO, and UICC, the founding of a new academic society in Asia (Asian Oncology Society, AOS), prospects for the preparation of Asian guidelines, and the promotion of FACO-centered clinical studies,
(4) Advances in cancer treatment and regenerative medicine, (5) Rare cancers and cancers in adolescents and young adults: establishing a treatment system, including networks, and evaluating survivorship, (6) The future of clinical studies based on the New Clinical Trial Methodology and future prospects, and (7) Engagement of female physicians and healthcare professionals in cancer medicine in accordance with workstyle reforms and cancer patient survivorship issues represented by employment support for job seekers. The meeting will also feature sessions, debates, and workshops to discuss recent hot topics across all disciplines.
We will ensure that the meeting has something to offer everyone, including not only physicians, pharmacists, and nurses, but also many other healthcare professionals engaged in cancer medicine. In collaboration with oncologists from ASCO, ESMO, and other Asian countries, our Society looks forward to showcasing Japan’s advanced research in oncology to a global audience.
We look forward to welcoming you to Hakata in Kyushu, Japan.